RxDoctor Payments Data

Howard Altman, MD

Urology · Philadelphia, PANPI 1134123102

Payments from drug & device makers

$2,100in general payments, 2019–2025

Across 76 payments — averaging $27.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$984
  • Johnson & Johnson$217
  • Sumitomo Pharma America, Inc.$160
  • Teleflex LLC$113
  • Medtronic$104
  • Ferring Pharmaceuticals Inc.$95
  • plus $426 from 13 others

What the payments were for

  • Food & beverage$1,80586%
  • Education$29514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,100 in reported general payments places this provider in the 45th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$202,347
Medicare patients
683
Services billed
3,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron636$373,060
XtandiEnzalutamide19$177,532
Tamsulosin Hcl1,467$24,246
Methenamine Hippurate109$11,270
Finasteride648$9,886
GemtesaVibegron18$8,616
Mirabegron ErMirabegron16$7,823
Solifenacin Succinate266$7,219
Tolterodine Tartrate ErTolterodine Tartrate38$3,440
Dutasteride93$3,332
Alfuzosin Hcl ErAlfuzosin Hcl200$3,189
Silodosin47$2,944
Pentoxifylline39$1,239
Oxybutynin Chloride23$1,165
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip56$947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq, Xtandi$984$550,592655 claims
Sumitomo Pharma America, Inc.Gemtesa$160$8,61618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 596 urology providers in Pennsylvania.

Other urology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →